ZA200706353B - Pyrazolo-pyrimidine derivatives as mGluR2 antagonists - Google Patents

Pyrazolo-pyrimidine derivatives as mGluR2 antagonists

Info

Publication number
ZA200706353B
ZA200706353B ZA200706353A ZA200706353A ZA200706353B ZA 200706353 B ZA200706353 B ZA 200706353B ZA 200706353 A ZA200706353 A ZA 200706353A ZA 200706353 A ZA200706353 A ZA 200706353A ZA 200706353 B ZA200706353 B ZA 200706353B
Authority
ZA
South Africa
Prior art keywords
pyrazolo
pyrimidine derivatives
mglur2 antagonists
mglur2
antagonists
Prior art date
Application number
ZA200706353A
Other languages
English (en)
Inventor
Gatti Mcarthur Silvia
Wichmann Juergen
Goetschi Erwin
Woltering Thomas Johannes
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200706353B publication Critical patent/ZA200706353B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200706353A 2005-02-11 2007-07-31 Pyrazolo-pyrimidine derivatives as mGluR2 antagonists ZA200706353B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101027 2005-02-11

Publications (1)

Publication Number Publication Date
ZA200706353B true ZA200706353B (en) 2009-09-30

Family

ID=36090752

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200706353A ZA200706353B (en) 2005-02-11 2007-07-31 Pyrazolo-pyrimidine derivatives as mGluR2 antagonists

Country Status (18)

Country Link
US (1) US7361659B2 (xx)
EP (1) EP1851225B1 (xx)
JP (1) JP4708438B2 (xx)
KR (1) KR100968291B1 (xx)
CN (1) CN101115755B (xx)
AR (1) AR052568A1 (xx)
AT (1) ATE512966T1 (xx)
AU (1) AU2006212457B2 (xx)
BR (1) BRPI0607927A2 (xx)
CA (1) CA2597608C (xx)
ES (1) ES2365406T3 (xx)
IL (1) IL184712A (xx)
MX (1) MX2007009106A (xx)
NO (1) NO20073876L (xx)
RU (1) RU2402553C2 (xx)
TW (1) TW200716120A (xx)
WO (1) WO2006084634A1 (xx)
ZA (1) ZA200706353B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085398A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009110901A1 (en) * 2008-03-06 2009-09-11 Sanofi-Aventis Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur
US8207181B2 (en) 2008-03-06 2012-06-26 Sanofi Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof
WO2012020820A1 (ja) 2010-08-11 2012-02-16 大正製薬株式会社 ヘテロアリール－ピラゾール誘導体
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
US9957271B2 (en) 2011-10-20 2018-05-01 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
JP2015534993A (ja) 2012-10-23 2015-12-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａ 自閉症性障害の処置のためのｍＧｌｕ２／３アンタゴニスト
EP3134089A2 (en) 2014-04-23 2017-03-01 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of intellectual disabilities
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
AU2015342883B2 (en) 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
EP3215511B1 (en) 2014-11-06 2024-04-17 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
ES2958391T3 (es) 2014-11-06 2024-02-08 Bial R&D Invest S A Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
ES2727158T3 (es) 2014-12-03 2019-10-14 Janssen Pharmaceutica Nv Ligandos para PET de mGluR2 radiomarcados
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
SI3389727T1 (sl) 2015-12-18 2020-10-30 Janssen Pharmaceutica Nv Radioaktivno označeni ligandi PET MGLUR2/3
US11045562B2 (en) 2015-12-18 2021-06-29 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
EP3440080A4 (en) 2016-04-06 2020-01-22 Lysosomal Therapeutics Inc. PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US11124516B2 (en) 2016-04-06 2021-09-21 BIAL-BioTech Investments, Inc. Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
MX2018012208A (es) 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
US11168087B2 (en) 2016-05-05 2021-11-09 Bial—R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
CN110225781B (zh) * 2017-01-09 2022-05-17 辉诺生物医药科技（杭州）有限公司 噻唑衍生物及其应用
CN111601811B (zh) 2017-11-24 2023-05-05 住友制药株式会社 6,7-二氢吡唑并[1,5-a]吡嗪酮衍生物和其医药用途
KR102535452B1 (ko) * 2018-07-06 2023-05-26 파에노 테라퓨틱스 씨오., 엘티디. 티아졸 화합물의 결정형 및 이의 응용

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199800792T2 (xx) 1996-02-07 1998-07-21 Janssen Pharmaceutica N.V. CRF resept�r antagonistleri olarak pirazolopirimidinler.
SI0891978T1 (en) 1997-07-18 2002-06-30 F. Hoffmann-La Roche Ag 5H-Thiazolo (3,2-a) pyrimidine derivatives
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
DK1379511T3 (da) * 2001-04-12 2005-11-07 Hoffmann La Roche Dihydro-benzo[b][1,4]diazepin-2-on-derivater som mGLuR2-antagonister II
ATE387435T1 (de) * 2003-04-15 2008-03-15 Astrazeneca Ab Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
JP4608542B2 (ja) * 2004-06-21 2011-01-12 エフ．ホフマン−ラ ロシュ アーゲー ピラゾロピリミジン誘導体

Also Published As

Publication number Publication date
IL184712A (en) 2013-05-30
CA2597608A1 (en) 2006-08-17
MX2007009106A (es) 2007-09-11
US7361659B2 (en) 2008-04-22
KR100968291B1 (ko) 2010-07-07
IL184712A0 (en) 2007-12-03
NO20073876L (no) 2007-09-10
US20060183756A1 (en) 2006-08-17
JP2008530042A (ja) 2008-08-07
CN101115755B (zh) 2013-01-16
KR20070104592A (ko) 2007-10-26
TW200716120A (en) 2007-05-01
JP4708438B2 (ja) 2011-06-22
RU2007128624A (ru) 2009-03-20
BRPI0607927A2 (pt) 2009-10-20
CA2597608C (en) 2013-12-24
AU2006212457B2 (en) 2011-04-14
AU2006212457A1 (en) 2006-08-17
WO2006084634A1 (en) 2006-08-17
RU2402553C2 (ru) 2010-10-27
EP1851225A1 (en) 2007-11-07
EP1851225B1 (en) 2011-06-15
ES2365406T3 (es) 2011-10-04
ATE512966T1 (de) 2011-07-15
AR052568A1 (es) 2007-03-21
CN101115755A (zh) 2008-01-30

Similar Documents

Publication Publication Date Title
ZA200706353B (en) Pyrazolo-pyrimidine derivatives as mGluR2 antagonists
IL185692A0 (en) Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists
ZA200803811B (en) Neuropolin antagonists
EP1928237A4 (en) NEW HETEROCYCLES BASED ON IMIDAZO
IL189856A0 (en) New formulation
HK1129305A1 (zh) 取代的 -氨基-吡咯並三嗪衍生物
PL1879451T3 (pl) Innowacyjna formulacja
TWI370115B (en) New formulation
HK1120269A1 (en) Pyrimidine derivatives
AP2007004047A0 (en) Substituted triazole derivatives as oxtocin antagonists
GB0525080D0 (en) Pyrimidine derivatives
GB0525083D0 (en) Pyrimidine derivatives
IL185326A0 (en) PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS
PL1954674T3 (pl) Nowe pochodne N-fenetylokarboksyamidu
ZA200804335B (en) Substituted bicyclic pyrimidone derivatives
GB0525081D0 (en) Pyrimidine derivatives
GB0526419D0 (en) Formulation
IL184841A0 (en) Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives
GB0517673D0 (en) Formulation
EP1854446A4 (en) ANTIALLERGIC COMPOSITION
IL192308A0 (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
GB0501030D0 (en) Formulation
LT1928232T (lt) Kieta kompozicija
GB0508681D0 (en) Antagonist
GB0514579D0 (en) Substituted benzyloxy-phenylmethylamide derivatives